Cantor Fitzgerald analyst Louise Chen said she believes the 5% pullback in Amarin (AMRN) shares is related to headlines that there is a document that says Vascepa has been deemed by UnitedHealth (UNH) to be a "non-preferred" drug that requires prior authorization. However she said the drugmaker confirmed that "this is old news" since UnitedHealth has always been an outlier. If anything, she believes the reimbursement situation with UnitedHealth "could get better quickly" now that Vascepa has a broad label and she views the pullback amid this "noise" could be a good buying opportunity. Chen maintains an Overweight rating and $35 price target on Amarin shares.

Deutsche Bank analyst George Hill raised the firm's price target on UnitedHealth to $562 from $545 and keeps a Buy rating on the shares. The company reported a Q1 earnings beat with many moving pieces caused by the cyberattack on Change Healthcare, which left earnings quality and guidance up to investor interpretation, the analyst tells investors in a research note. The firm sees the full impact of the hack, as well as conservatism around cost trend and utilization would impact UnitedHealth earnings by only 2% for the full year.

Notable gainers among liquid option names this morning include Genuine Parts (GPC) $159.09 +15.03, Globe Life (GL) $66.97 +3.74, Anthem (ELV) $532.10 +23.13, United Continental (UAL) $50.59 +1.84, and UnitedHealth (UNH) $494.80 +15.81.

Unusual total active option classes on open include: Wrap Technologies (WRAP), AstraZeneca (AZN), JetBlue (JBLU), United Continental (UAL), Taiwan Semi (TSM), Nokia (NOK), EBay (EBAY), Maplebear Inc (CART), Airbnb (ABNB), and UnitedHealth (UNH).

RBC Capital analyst Ben Hendrix lowered the firm's price target on UnitedHealth to $555 from $596 but keeps an Outperform rating on the shares. The company reported a "better than feared" Q1, but the debate over utilization trends is expected to persist through the first half as excess reserves skew the medical care ratio picture, the analyst tells investors in a research note. RBC also notes that its added caution reflects UnitedHealth's "reduced claims visibility".